137 related articles for article (PubMed ID: 34307912)
1. Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma.
Khanolkar RA; Quon H; Thind K; Sia M; Roumeliotis M; Husain S; McGeachy P; Meyer T; Martell K
Clin Transl Radiat Oncol; 2021 Sep; 30():38-42. PubMed ID: 34307912
[TBL] [Abstract][Full Text] [Related]
2. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients.
Boehle A; Zywietz D; Robrahn-Nitschke I; Lusch A; König IR
Urol Oncol; 2023 Nov; 41(11):454.e17-454.e24. PubMed ID: 37714724
[TBL] [Abstract][Full Text] [Related]
3. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.
King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF
Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060
[TBL] [Abstract][Full Text] [Related]
4. Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer.
Kusuhara Y; Fukawa T; Fukumori T; Ueno Y; Daizumoto K; Sasaki Y; Tomida R; Yamamoto Y; Yamaguchi K; Tonoiso C; Kubo A; Kawanaka T; Furutani S; Ikushima H; Kanayama HO; Takahashi M
Anticancer Res; 2023 Oct; 43(10):4627-4635. PubMed ID: 37772553
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
6. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
8. Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.
Bracci S; Osti MF; Agolli L; Bertaccini L; De Sanctis V; Valeriani M
Radiat Oncol; 2016 Jun; 11():78. PubMed ID: 27276878
[TBL] [Abstract][Full Text] [Related]
9. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.
Zumsteg ZS; Zelefsky MJ; Woo KM; Spratt DE; Kollmeier MA; McBride S; Pei X; Sandler HM; Zhang Z
BJU Int; 2017 Nov; 120(5B):E87-E95. PubMed ID: 28464446
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
11. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients.
Martell K; Mendez LC; Chung HT; Tseng CL; Alayed Y; Cheung P; Liu S; Vesprini D; Chu W; Wronski M; Szumacher E; Ravi A; Loblaw A; Morton G
Radiother Oncol; 2019 Dec; 141():149-155. PubMed ID: 31522882
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer.
Vuolukka K; Auvinen P; Palmgren JE; Voutilainen T; Aaltomaa S; Kataja V
Brachytherapy; 2019; 18(5):583-588. PubMed ID: 31227400
[TBL] [Abstract][Full Text] [Related]
14. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
15. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R
Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381
[TBL] [Abstract][Full Text] [Related]
16. Estimated absolute percentage of biopsied tissue positive for Gleason pattern 4 (eAPP4) in low dose rate prostate brachytherapy: Evaluation of prognostic utility in a large cohort.
Casey G; Quon H; Meyer T; Sia M; Thind K; Das S; Cho D; McGeachy P; Husain S; Martell K
Radiother Oncol; 2023 Nov; 188():109859. PubMed ID: 37604278
[TBL] [Abstract][Full Text] [Related]
17. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
[TBL] [Abstract][Full Text] [Related]
18. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
19. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.
Lazarev S; Thompson MR; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):781-790. PubMed ID: 29319928
[TBL] [Abstract][Full Text] [Related]
20. How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?
Urabe F; Kimura T; Sasaki H; Tashiro K; Iwatani K; Yasue K; Aoki M; Sato S; Takahashi H; Miki K; Egawa S
Int J Clin Oncol; 2022 Jan; 27(1):184-193. PubMed ID: 34599724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
